BKI-1369 Catalog No.:M31153-C orally active and selective SGLT1

orally active and selective SGLT1 inhibitor

2-trifluoro-N-(1-((1-(4-fluorophenyl)-1H-indazol-5-yl)oxy)-1-(3-methoxyphenyl)-2-propanyl)acetamide

Smiles: COC1=CC=C(C=C1O)/C=C/C1C=C(C=C(O)C=1)O[C@@H]1O[C@H](COC(=O)C2=CC(O)=C(O)C(O)=C2)[C@@H](O)[C@H](O)[C@H]1O

FR901464 induces characteristic G1 and G2/M phase arrest in the cell cycle and internucleosomal degradation of genomic DNA with the same kinetics as activation of SV40 promoter-dependent cellular transcription in M-8 tumor cells

88 nM in biochemical assay)

BKI-1369 Catalog No.:M31153-C orally active and selective SGLT1BKI 1369 is a bumped kinase inhibitor (BKI). BKI 1369 increases human Ether a go go related gene (hERG) inhibitory activity with an IC50 of 1. 52 M. BKI 1369 reduces the parasite burden and diseases severity in the gnotobiotic pig model. BKI 1369 has been well characterized for potency, stability, metabolism, toxicity, pharmacokinetics and is potent against C. parvum in infected mice and calves. Product information CAS Number: 1951431 22 3 Molecular